Results were in line with reaffirmed guidance, with core operating income flat in Q2. The key swing factors to watch are Entresto's continued generic erosion trajectory and the outcome of the Lutathera patent appeal. Pipeline catalysts in H2 include Kisqali overall survival data and regulatory decisions for Cosentyx in PMR and ianalumab in Sjögren's. The elevated debt load from M&A may limit near-term buyback acceleration.
Drugs in focus
NVS drug pipeline →Cosentyx
● Neutral Named in this 6-K- Impact
- Phase
- Approved (marketed); additional Phase 3 programs completed/terminated
- Time to market
- Already marketed — approved in the US since January 2015; label-expansion filings for PMR/GCA are possible but no submission or decision date is recorded.
- Next catalyst
- None dated
What to watchWatch for Novartis disclosures on the completed PMR (381 patients, primary completion Sept 2025) and GCA (354 patients) Phase 3 programs, a regulatory submission for either would be the next meaningful Cosentyx catalyst, though it would move a ~$156 mega-cap modestly. Also track IL-17 competition and any biosimilar entry, plus the next quarterly 6-K for Cosentyx sales trajectory.
- ● Fabhalta 4/10 Approved (marketed); Phase 3 readout pending in aHUS Named in filing
- ● Scemblix 4/10 Approved (pivotal Phase 3 ASCEMBL completed; additional Phase 2/3 studies mostly completed or terminated) Named in filing
- ▼ Entresto 3/10 Approved / marketed (adult HFrEF, 2015; pediatric heart failure via Entresto Sprinkle, 2024). No pending pivotal trials Named in filing
- ● Ilaris 3/10 Approved (marketed); label-expansion programs: Phase 3 (AOSD, Japan) completed; Phase 3 (first-line NSCLC) terminated Named in filing
- ● Lucentis 3/10 Approved (marketed) Named in filing
- 16 more · All NVS drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 21 $153.87entry
- T+1 · 4mo ago −0.51%α −0.40% · $153.08
- T+5 · 4mo ago +1.46%α +2.68% · $156.11
- T+20 · 3mo ago +0.44%α −2.12% · $154.55
- T+60 · 5w ago −7.45%α −11.42% · $142.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with core operating income flat at $5.9B (0% cc). Net income declined -19% to $3.3B due to higher taxes and interest expense. Full-year guidance was reaffirmed: low single-digit net sales growth and low single-digit core operating income decline. Strong growth from Kisqali (+43% cc), Kesimpta (+32% cc), and Scemblix (+89% cc) was offset by generic erosion of Entresto (-51% cc). Net debt rose to $39.4B following the $12B Avidity acquisition.
Key Facts
- Q2 net sales $14.4B (+3% USD, +1% cc); H1 net sales $27.5B (+1% USD, -2% cc)
- Q2 core operating income $5.9B (flat cc); core EPS $2.41 (0% USD, -1% cc)
- Q2 net income $3.3B (-19% cc); EPS $1.71 (-18% cc)
- Q2 free cash flow $5.6B (-12%)
- Full-year 2026 guidance reaffirmed: net sales low single-digit growth, core operating income low single-digit decline (cc)
- Kisqali +43% cc, Kesimpta +32% cc, Scemblix +89% cc, Pluvicto +43% cc, Leqvio +59% cc
- Entresto -51% cc due to US generic competition; Promacta -65% cc, Tasigna -58% cc
- Lutathera patent invalidity ruling in Delaware; appeal filed
- Avidity acquisition closed Feb 2026 for ~$12B; Pikavation ($1.8B) and Excellergy ($0.9B) closed in Q2
- Net debt increased to $39.4B from $21.9B at Dec 2025; debt/equity ratio 1.12:1
- Share buyback: $2.8B in H1 2026; $5.6B remaining under $10B program
Financial Impact
Q2 net sales +3% USD, operating income -2%, net income -19%. Core operating income flat. H1 net sales +1%, operating income -6%, net income -16%. Net debt increased $17.5B to $39.4B.
Risk Factors
- Lutathera patent invalidity ruling could open door to generic competition if appeal fails
- Entresto sales declining ~50% YoY due to US generics, a major headwind to total revenue
- Net debt of $39.4B and debt/equity ratio of 1.12:1 increase financial leverage
- Higher interest expense ($462M in Q2 vs $289M) pressuring net income
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001114448-26-000012 |
| Document: nvs-20260630-99_1.htm | 0001114448-26-000012 |
| Document: nvs-20260630.htm | 0001114448-26-000012 |
| Document: 0001114448-26-000012-index-headers.html | 0001114448-26-000012 |
| Document: 0001114448-26-000012-index.html | 0001114448-26-000012 |
| Document: 0001114448-26-000012.txt | 0001114448-26-000012 |
Track record
16 reports on NVS
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $160.50 to $160.20 Now $160.20 −0.19% ▼ −0.19% +1.72% vs SPY
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
- Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
- Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
- Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
- Oct 13, 20265w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
- Sep 4, 202610w ago 6-K Bearish 6/10 Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
- Aug 4, 202615w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers